One study showed that persister cells of different cancers (breast, melanoma, lung, and ovarian cancers) were vulnerable to GPX4 inhibition, which led to the accumulation of lipid hydroperoxides and ferroptosis upon the withdrawal of ferrostatin-1, a ferroptosis-rescuing antioxidant. Here, GPX4 is linked to cancer.